ANVS insider Form 4 shows director buying Annovis Bio stock

Rhea-AI Filing Summary

A director of Annovis Bio, Inc. (ANVS) reported several open-market purchases of the company’s common stock. On 11/24/2025, the director bought blocks of Annovis Bio common shares at prices of $4.13, $3.85, $4.14, and $4.15 per share, each coded as a purchase transaction.

Following these transactions, the director beneficially owns 2,519,739 shares of Annovis Bio common stock directly. In addition, 223,357 shares are held indirectly through The 2018 Jane and Michael Hoffman Descendants Trust, over which the reporting person has voting and investment power. The filing confirms the director’s status and that the report is filed for a single reporting person.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hoffman Michael B

(Last) (First) (Middle)

C/O ANNOVIS BIO, INC.

101 LINDENWOOD DR, SUITE 225

(Street)

MALVERN PA 19355

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Annovis Bio, Inc. [ ANVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/24/2025		P		1,489	A	$4.13	2,482,028	D
Common Stock	11/24/2025		P		9,200	A	$3.85	2,491,228	D
Common Stock	11/24/2025		P		415	A	$4.14	2,491,643	D
Common Stock	11/24/2025		P		28,096	A	$4.15	2,519,739	D
Common Stock								223,357	I	The 2018 Jane and Michael Hoffman Descendants Trust(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares are held in a family trust formed by the reporting person and the reporting person has voting and investment power over such shares.

	/s/ Maria Maccecchini Attorney-in-Fact	11/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Annovis Bio (ANVS) report?

A director of Annovis Bio, Inc. reported multiple open-market purchases of the company’s common stock on 11/24/2025, all coded as buy transactions.

At what prices did the Annovis Bio (ANVS) director purchase shares?

The director bought Annovis Bio common stock at $4.13, $3.85, $4.14, and $4.15 per share on 11/24/2025.

How many Annovis Bio (ANVS) shares does the director now own directly?

After the reported transactions, the director directly owns 2,519,739 shares of Annovis Bio common stock.

What is the indirect Annovis Bio (ANVS) shareholding reported?

The filing shows 223,357 shares held indirectly through The 2018 Jane and Michael Hoffman Descendants Trust, with the reporting person holding voting and investment power.

What is the relationship of the reporting person to Annovis Bio (ANVS)?

The reporting person is identified as a Director of Annovis Bio, Inc., as indicated in the relationship section of the Form 4.

Is this Annovis Bio (ANVS) Form 4 filed by one or multiple insiders?

The Form 4 is indicated as filed by one reporting person, not by a group.